Mendelsohn, JB; Spiegel, P; Grant, A; Doraiswamy, S; Schilperoord, M; Larke, N; Burton, JW; Okonji, JA; Zeh, C; Muhindo, B; Mohammed, IM; Mukui, IN; Patterson, N; Sondorp, E; Ross, DA (2017) Low levels of viral suppression among refugees and host nationals accessing antiretroviral therapy in a Kenyan refugee camp. Conflict and health, 11. p. 11. ISSN 1752-1505 DOI: https://doi.org/10.1186/s13031-017-0111-3

Downloaded from: http://researchonline.lshtm.ac.uk/3983347/

DOI: 10.1186/s13031-017-0111-3

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by/2.5/
Low levels of viral suppression among refugees and host nationals accessing antiretroviral therapy in a Kenyan refugee camp

Joshua B. Mendelsohn1,2*, Paul Spiegel3,10, Alison Grant4, Sathyanarayanan Doraiswamy5, Marian Schilperoord3, Natasha Larke2, John Wagacha Burton4, Jully A. Okonji5,11, Clement Zeh6, Bosco Muhindo4, Ibrahim M. Mohammed7, Irene N. Mukui7, Njogu Patterson3, Egbert Sondorp8 and David A. Ross2,9

Abstract

Background: Refugees and host nationals who accessed antiretroviral therapy (ART) in a remote refugee camp in Kakuma, Kenya (2011–2013) were compared on outcome measures that included viral suppression and adherence to ART.

Methods: This study used a repeated cross-sectional design (Round One and Round Two). All adults (≥18 years) receiving care from the refugee camp clinic and taking antiretroviral therapy (ART) for ≥30 days were invited to participate. Adherence was measured by self-report and monthly pharmacy refills. Whole blood was measured on dried blood spots. HIV-1 RNA was quantified and treatment failures were submitted for drug resistance testing. A remedial intervention was implemented in response to baseline testing. The primary outcome was viral load <5000 copies/mL. The two study rounds took place in 2011-2013.

Results: Among eligible adults, 86% (73/85) of refugees and 84% (86/102) of Kenyan host nationals participated in the Round One survey; 60% (44/73) and 58% (50/86) of Round One participants were recruited for Round Two follow-up viral load testing. In Round One, refugees were older than host nationals (median age 36 years, interquartile range, IQR 31, 41 vs 32 years, IQR 27, 38); the groups had similar time on ART (median 147 weeks, IQR 38, 64 vs 139 weeks, IQR 39, 225). There was weak evidence for a difference in the proportion of refugees and host nationals who were virologically suppressed (<5000 copies/mL) after 25 weeks on ART (58% vs 43%, p = 0.10) and no difference in the proportions suppressed at Round Two (74% vs 70%, p = 0.66). Mean adherence within each group in Round One was similar. Refugee status was not associated with viral suppression in multivariable analysis (adjusted odds ratio: 1.69, 95% CI 0.79, 3.57; p = 0.17). Among those not suppressed at either timepoint, 69% (9/13) exhibited resistance mutations.

Conclusions: Virologic outcomes among refugees and host nationals were similar but unacceptably low. Slight improvements were observed after a remedial intervention. Virologic monitoring was important for identifying an underperforming ART program in a remote facility that serves refugees alongside host nationals. This work highlights the importance of careful laboratory monitoring of vulnerable populations accessing ART in remote settings.

Keywords: Kenya, Refugee, Migration, Antiretroviral therapy, Adherence, HIV
Background
Life-long antiretroviral therapy (ART) that requires consistent access to medications and supportive services is a challenge in conflict-affected settings. By the end of 2013, 172 million people were affected by violent conflict worldwide, while 51.2 million people were forcibly displaced as a result of conflict, persecution, generalized violence, and human rights violations [1, 2]. Of these, 16.7 million were classified as refugees who had crossed an international border to escape a well-founded fear of persecution in the absence of protection in their home country. International humanitarian and refugee law suggest that refugees should receive an equivalent standard of medical care to host nationals in countries where they have sought protection [3]. In many settings, refugees and host nationals receive HIV services from the same facilities. An equivalent standard of HIV care should result in similar treatment outcomes. Few studies, however, have sought to rigorously compare HIV treatment outcomes between refugee and host national groups. Previous work has shown high levels of adherence to ART, increases in CD4 counts, and increases in survival among conflict-affected populations [4, 5]. In a study comparing urban refugees situated in Kuala Lumpur with Malaysian host nationals, we found comparable levels of viral suppression [6]. Refugees, however, live in a variety of settings (e.g., camps, cities, etc.), and it is not known how these different environments might influence their HIV treatment outcomes [7]. Better data will help governments and humanitarian agencies improve ART delivery, while retaining more people along the HIV cascade of care [8]. We report on a repeated cross-sectional study of adherence and viral suppression among refugees and host nationals accessing ART in Kakuma Refugee Camp, Kenya, pre- and post- a remedial intervention that responded to poor baseline levels of viral suppression. Our aim was to compare viral suppression and adherence to ART among refugees and host nationals and to identify factors associated with viral suppression.

Methods
Study setting
Kakuma Refugee Camp is situated in a remote part of Northwestern Kenya. In 2011, the camp’s Comprehensive Care Clinic was managed by the International Rescue Committee (IRC) and was overseen by the United Nations High Commissioner for Refugees (UNHCR). At study initiation (February 2011), the camp population was 82,409 (Somalia, 54%; Sudan, 32%; Ethiopia, 8%; Democratic Republic of the Congo, 5%). Local host nationals were primarily Turkana, a nomadic-pastoralist group. Adult HIV prevalence within the camp was 1.2% [9]. Clients who tested positive for HIV were counseled and started on multivitamins and cotrimoxazole, followed by ART at CD4 < 250 cells/ul. After six months on ART, clinic appointments were scheduled every six months; however, clients typically presented at the clinic pharmacy on a monthly basis to refill their ART prescriptions. At this time, they could request a counseling session with a nurse or community support worker. First-line regimens consisted of two nucleoside reverse transcriptase inhibitors (NRTIs), usually lamivudine with zidovudine, stavudine or tenofovir, combined with a non-nucleoside reverse transcriptase inhibitor (NNRTI) such as nevirapine or efavirenz, given twice daily. Six months prior to the study, stavudine was phased out as per 2009 World Health Organization (WHO) recommendations. Routine CD4-testing, counseling services, and nutritional supplementation including additional rations of cornmeal and peanut-based nutritional spread were provided to ART clients.

Study design
This study used a repeated cross-sectional design with baseline (Round One) and follow-up (Round Two) segments. We initially designed the baseline cross-sectional survey. Round Two was initiated on the basis of Round One results.

Round One
A five-week cross-sectional survey was implemented between February and April 2011. All adults were invited to participate if they accessed their treatment from the Comprehensive Care Clinic, were ≥18 years old, had been taking ART for ≥30 days, had not missed ≥6 consecutive monthly pharmacy refills, and were not exclusively on ART for prevention of mother-to-child transmission. Recruitment occurred during regular clinic appointments or through an active recruitment protocol implemented by community health workers. Three attempts were made to contact all eligible adults by telephone or home visit.

Round Two
In response to very low proportions of participants who were virally suppressed in Round One, a remedial intervention was implemented by IRC in December 2011 that aimed to improve elements of the ART program. Intervention measures included hiring an additional clinical officer and a full-time adherence support counselor, construction of an additional adherence counseling room, pill counting during appointments, closer monitoring of the ART surveillance database, increased frequency of CD4 monitoring (once per year increased to twice per year), additional training for peer support counselors, additional adherence counseling during appointments, and intensified monitoring of clients with viral loads ≥5000 copies/mL. Baseline participants were re-contacted between September 2012 and June 2013 and invited to
provide a Round Two follow-up viral load. Survey questionnaires were not completed in Round Two. Following Kenyan national guidelines, clients with a second consecutive viral load of ≥5000 copies/mL were switched to second-line ART.

Data sources and measures
A structured questionnaire was administered during Round One. Data was collected on a pen and paper survey administered in a face-to-face interview conducted in the respondent's language of choice (usually the mother tongue). Prior to pre-testing, the questionnaire was translated from English into Swahili, Nga’turkana, Somali, French and Juba Arabic, and back-translated into English by an independent translator. Both versions were then reconciled. HIV RNA-1 concentrations were measured using dried blood spots collected on Whatman 903 filter paper and stored at -20 °C in the refugee camp pharmacy storage facility. Samples were shipped on dry ice to collaborating Kenya Medical Research Institute (KEMRI) laboratories. Self-reported adherence was measured using a 4-day dose-by-dose recall and a one-month recall visual analogue scale where participants were asked to mark an “X” representing the amount of medication they had taken during the previous month at any point along a 10 cm line [10, 11]. Adherence to pharmacy prescription refill schedule was estimated from pharmacy records as the proportion of refills collected divided by the total number of refills prescribed in the 24 months prior to the baseline interview or since the month of ART initiation, whichever was longer. The primary outcome was viral load <5000 copies/mL, consistent with WHO recommendations on minimum cut-offs for viral loads measured from dried spots [12].

Laboratory procedures
Viral loads were analyzed on the COBAS Ampliprep/Taqman platform (Roche Diagnostics Systems, Branchburg, New Jersey, USA). Round One samples from clients with two consecutive viral loads ≥5000 copies/mL were submitted for drug resistance testing. Sequencing was performed using a WHO-accredited in-house genotyping assay. Sequenced samples were analyzed on an ABI Prism 3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) and edited using RECall v2.0 Software, using HIV-1 HXB2 as the reference sequence [13]. Protease (PR) and reverse transcriptase (RT) fragments were confirmed against the Stanford University HIV Drug Resistance Database Version 7.0 (http://hivdb.stanford.edu/) and the International AIDS Society Mutation List [14, 15].

Statistical methods
Medians, proportions and corresponding 95% confidence intervals (95% CI) were used to compare outcomes. Risk factors were evaluated using unconditional logistic regression. Effect estimates included odds ratios (OR) and corresponding 95% CIs. A three-level hierarchical, step-wise modelling approach was used to order the entry of factors in multivariable models. Social action theory, which emphasizes the influence of social interaction and environmental structures on problem-solving activities affecting health behaviors [16], was selected as the conceptual framework given its consideration of socio-structural factors relevant for refugee camp settings. Drawing on social action theory, factors were grouped into levels representing “treatment contexts” i.e., socio-demographic factors; “self-change factors” i.e., knowledge measures; and “action state factors” i.e., adherence measures (see Additional files 1, 2 and 3). Associations with viral suppression were evaluated in univariable analyses using log-likelihood ratio tests. The “treatment context model” was fitted by adjusting for factors with p < 0.2 in univariable analyses. The “self-change model” was fitted by adjusting for all retained factors from the prior level, then adjusting again for any additional self-change factors meeting the p < 0.2 threshold. Given detected collinearities, the “action state model” was adjusted by factors from previous model levels, but not by additional factors within this level. The final multivariable model sequentially excluded factors with the highest p-values, until all factors met a p < 0.05 cut-off. Refugee status, age, and time on ART were retained throughout modelling as a priori covariates of interest. Given that adjustment by mediating factors can introduce over-adjustment bias, adherence factors were not included in the final model [17].

Results
Study population
Among eligible HIV-positive clients who were enrolled in the ART program, 86% (73/85) of refugees and 84% (86/102) of Kenyan host nationals participated in Round One. Among refugees, 11% (9/85) declined and 4% (3/85) were not found; among host nationals 6% (6/102) declined and 10% (10/102) were not found (Fig. 1). Viral loads were collected from 159 clients during Round One, 83% (131/159) of whom were on treatment for ≥25 weeks and included in analyses. Refugees reported a median time in the host country of 9.8 years (IQR 4.5, 15.7), and median time since registration with UNHCR of 8.5 years (IQR 2.8, 14.9). HIV-positive adults from the refugee and host community had similar proportions of women (67% vs 66%, p = 0.91) while having comparable median durations on ART (147 vs 139 weeks, p = 0.65). Refugees
were older than host nationals (median age 36 years vs 32 years, \( p = 0.02 \)) (Table 1).

**Round One**

**Virologic outcomes and adherence**

Of all clients on treatment for \( \geq 25 \) weeks, 50\% (65/131) had viral loads <5000 copies/mL. There was weak evidence that a higher proportion of refugees were suppressed at this level when compared with host nationals (58\% vs 43\%; \( p = 0.10 \)). There was strong evidence, however, that refugees had a lower median viral load at baseline (3,830 copies/mL vs 7,905; \( p = 0.03 \)) (Table 2). Mean adherence to pharmacy refill schedule was 95.6\% (95\%CI: 91.6, 99.6) for refugees, compared with 90.7\% (95\%CI 91.6, 99.6) for host nationals (\( p = 0.11 \)) (Additional file 4). Comparing refugees and host nationals on adherence measured by 4-day self-report (94.2\% vs 92.2\%, \( p = 0.62 \)) and 1-month visual analogue scale (90.8\% vs 87.3\%, \( p = 0.26 \)) revealed only minor differences between groups.

**Factors associated with virologic outcomes**

Within the “treatment contexts level” (Additional file 1), \( \geq 48 \) weeks between HIV diagnosis and ART start was associated with a fourfold increase in the odds of viral suppression (AOR: 3.98, 95\% CI 1.44, 11.01; \( p\text{-trend} = 0.006 \)). The weak association between refugee status and viral suppression in crude analyses (OR: 1.88, 95\% CI 0.93, 3.81; \( p = 0.08 \)) was further attenuated after adjusting for age group, time on ART, time from HIV diagnosis to ART start, place of ART start, refill difficulties, and food security (AOR: 0.51, 95\% CI 0.08, 3.18; \( p = 0.46 \)). No evidence was found for associations with “self-change factors” (Additional file 2). Among exposures in the “action state” model, self-reported adherence to medication schedule (AOR: 2.80, 95\% CI 0.99, 7.90; \( p = 0.04 \)) and self-reported dosing schedule (i.e., correct reporting of dosing schedule) were associated with viral suppression (AOR: 3.33, 95\% CI 1.20, 9.24; \( p = 0.02 \)) (Additional file 3). There was also evidence that self-reported adherence over the past month was associated with decreased odds of viral suppression (AOR = 0.71, 95\% CI 0.44, 1.14; \( p = 0.05 \)). This association may have been confounded by adjustment for refill difficulties in the past three months. The magnitude of this confounding was 58\% (OR = AOR/AOR).

In the final multivariable model (Table 3), longer duration between HIV diagnosis and ART start (\( \geq 48 \) weeks, AOR: 3.61, 95\% CI 1.37, 9.47; \( p\text{-trend} = 0.01 \)), self-reported
### Table 1: Socio-demographic characteristics of refugees and host nationals

| Factor                                | Round One, all | Round One, ≥25 weeks on treatment | Round Two | Not included in Round Two |
|----------------------------------------|----------------|-----------------------------------|-----------|---------------------------|
|                                        | Refugee (n = 73) | Host (n = 86)                      | Refugee (n = 59) | Host (n = 72) | p-value | Refugee (n = 35) | Host (n = 43) | p-value | Refugee (n = 29) | Host (n = 36) | p-value |
| Age, median yrs (IQR)                  | 36 (31, 41)     | 32 (27, 38)                       | 0.02\(^a\)   | 37 (33, 43)     | 32 (27, 38) | 0.001\(^a\)   | 36 (33, 41)     | 28 (24, 38) | 0.02\(^a\)   | 39 (34, 43)     | 31 (27, 39) | 0.04\(^a\)   |
| Female gender                          | 49 (67)         | 57 (66)                           | 0.91        | 38 (64)         | 48 (67)   | 0.79        | 21 (60)         | 27 (63)   | 0.80        | 17 (71)         | 2 (72)     | 0.90        |
| No earned income\(^c\)                 | 63 (86)         | 70 (81)                           | 0.41        | 49 (83)         | 57 (79)   | 0.57        | 28 (80)         | 33 (78)   | 0.73        | 21 (88)         | 24 (83)    | 0.63        |
| Married/cohabiting                     | 29 (40)         | 39 (45)                           | 0.48        | 23 (39)         | 32 (44)   | 0.53        | 15 (43)         | 24 (56)   | 0.26        | 8 (33)           | 8 (28)     | 0.65        |
| Nationality                            |                |                                   |             |                |           |             |                |           |             |                |           |             |
| Kenyan                                 | 0 (0)           | 86 (100)                          | <0.001\(^b\)| 0 (0)           | 72 (100)  | <0.001\(^b\)| 0 (0)           | 43 (100)  | <0.001\(^b\)| 0 (0)           | 29 (100)  | <0.001\(^b\)|
| Somali, Ethiopian, Eritrean\(^d\)     | 36 (49)         | 0 (0)                             |             | 29 (49)         | 0 (0)     |             | 14 (40)         | 0 (0)     |             | 15 (63)         | 0 (0)      |             |
| Sudanese                               | 20 (27)         | 0 (0)                             |             | 18 (31)         | 0 (0)     |             | 14 (18)         | 0 (0)     |             | 4 (17)           | 0 (0)      |             |
| Rwandese, Congolese, Burundian         | 17 (23)         | 0 (0)                             |             | 12 (20)         | 0 (0)     |             | 7 (20)           | 0 (0)     |             | 5 (21)           | 0 (0)      |             |
| Travel for ≥1 continuous month in past year | 8 (11)       | 22 (26)                           | 0.02        | 7 (12)          | 20 (28)   | 0.03        | 3 (9)            | 8 (19)    | 0.21        | 4 (17)           | 12 (41)    | 0.05        |
| Self-reported consistent adherence to medication schedule | 51 (71) | 72 (84)                           | 0.05        | 44 (76)         | 60 (83)   | 0.29        | 26 (74)         | 38 (88)   | 0.11        | 18 (78)         | 22 (76)    | 0.84        |
| Incorrect ART dosing                   | 26 (36)         | 11 (13)                           | 0.001       | 20 (34)         | 8 (11)    | 0.002       | 13 (37)         | 4 (9)     | 0.003       | 7 (29)           | 4 (14)     | 0.17        |
| Time on ART, median wks (IQR)          | 147 (38, 264)   | 139 (39, 225)                     | 0.65\(^a\)  | 202 (86, 270)   | 165 (96, 240) | 0.25\(^a\) | 192 (80, 268)   | 190 (120, 235) | 0.59\(^a\) | 208 (87, 275)   | 120 (56, 242) | 0.29\(^a\) |
| Time from HIV diagnosis to ART, median wks (IQR) | 8 (0, 44)     | 15 (1, 56)                        | 0.26\(^a\)  | 4 (0, 23)       | 9 (0, 52) | 0.11\(^a\)  | 1 (0, 13)       | 9 (0, 56) | 0.04\(^a\)  | 10 (0, 67)        | 13 (1, 47) | 0.86\(^a\) |
| Time in host country, median wks (IQR) | 307 (234, 814)  | –                                 | –           | 525 (265, 886)  | –         | –           | 596 (309, 948)  | –         | –           | 506 (234, 809)   | –         | –          |

Values are numbers (%) unless otherwise stated; p-values are chi-square tests unless otherwise stated; IQR interquartile range
\(^a\)Mann-Whitney two-sample statistic (Wilcoxon rank-sum test)
\(^b\)Fisher’s exact test
\(^c\)Not including financial assistance provided within refugee camp
\(^d\)Somalis, Ethiopians, and Eritreans were grouped as Somalis often reported Ethiopian nationality to conceal identities
adherence to medication schedule (AOR: 3.12, 95% CI 1.14, 8.49; \( p = 0.02 \)), and self-reported dosing schedule (AOR: 2.52, 95% CI 0.96, 6.58; \( p = 0.05 \)), were strongly associated with viral suppression. There was no evidence for an association between refugee status and viral suppression (AOR: 1.69, 95% CI 0.79, 3.57; \( p = 0.17 \)). Age and time on ART were not associated with the outcome in any models. All effects in the final model were adjusted for age group, refugee status, time on ART, and time from HIV diagnosis to ART start.

Table 3

Final multivariable model showing factors associated with viral suppression among refugees and host nationals on ART for \( \geq 25 \) weeks at baseline in Kakuma, Kenya (\( N = 128 \))

| Factor | Prevalence <5000 copies/mL, n/N (%) | Crude odds ratio (95% CI) | p-value | Adjusted odds ratio (95% CI) | p-value |
|--------|----------------------------------|--------------------------|---------|-----------------------------|---------|
| Age group (years) \(^c\) | | | | | |
| 18+    | 14/31 (45) | 1 | \( p(tr) = 0.90 \) | 1 | \( p(tr) = 0.82 \) |
| 30+    | 33/63 (52) | 1.34 (0.56, 3.17) | 1.47 (0.57, 3.76) | 0.90 (0.31, 2.59) | |
| 40+    | 16/34 (47) | 1.08 (0.41, 2.87) | | | |

| Refugee status | | | | | |
| Host | 9/20 (45) | 1 | \( p = 0.08 \) | 1 | \( p = 0.17 \) |
| Refugee | 19/41 (46) | 1.88 (0.93, 3.81) | 1.69 (0.79, 3.57) | |

| Time on ART (years) \(^c\) | | | | | |
| 0- | 35/67 (52) | 1 | \( p(tr) = 0.49 \) | 1 | \( p(tr) = 0.76 \) |
| 1- | 30/71 (42) | 1.06 (0.36, 3.09) | 0.80 (0.26, 2.49) | |
| 2+ | 33/57 (58) | 1.34 (0.49, 3.64) | 1.00 (0.34, 2.95) | |

| Time from HIV diagnosis to ART start (weeks) \(^c\) | | | | | |
| 0- | 8/29 (28) | 1 | \( p(tr) = 0.006 \) | 1 | \( p(tr) = 0.01 \) |
| 24- | 6/13 (46) | 2.25 (0.58, 8.78) | 2.71 (0.66, 11.11) | |
| 48+ | 49/86 (57) | 3.48 (1.39, 8.72) | 3.61 (1.37, 9.47) | |

| Adherence to medication schedule, self-reported \(^b\) | | | | | |
| Inconsistent | 7/25 (28) | 1 | \( p = 0.02 \) | 1 | \( p = 0.02 \) |
| Consistent | 56/103 (54) | 3.06 (1.18, 7.96) | 3.12 (1.14, 8.49) | |

| Self-reported dosing schedule \(^b\) \(^d\) | | | | | |
| Incorrect dosing | 11/28 (39) | 1 | \( p = 0.23 \) | 1 | \( p = 0.05 \) |
| Correct dosing | 52/100 (52) | 1.67 (0.71, 3.93) | 2.52 (0.96, 6.58) | 

p-values are log likelihood ratio tests; CI, confidence interval

*Three clients with incomplete data were excluded

*Adjusted for all factors in table except adherence factors denoted by superscript \(^d\). Factors were not adjusted for adherence to avoid risk of over-adjustment bias given that adherence mediates viral load

*Factor modelled as a linear effect; \( p(tr) = p(trend) \)

*Incorrect dosing was determined by comparing self-reported dosing schedules to standard dosing schedules [45]

Table 2

Comparison of HIV viral loads among refugees and host nationals taking ART for \( \geq 25 \) weeks

| Viral load | Group | Total, N (100%) | <5000 copies/mL, n (%), Crude odds ratio (95% CI) | p-value | Median, copies/mL (IQR), p-value |
|------------|-------|----------------|-----------------------------------------------|---------|----------------------------------|
| Round One  | Refugee | 59 | 34 (58) | 1 | 3830 (1460, 14800) | 0.03 \(^a\) |
| Kenyan | 72 | 31 (43) | 1.14 (0.56, 2.28) | 0.76 | 7905 (2625, 38900) | |
| All | 131 | 65 (50) | 1.07 (0.50, 2.27) | 0.82 | 5010 (1920, 22400) | |
| Round Two | Refugee | 35 | 26 (74) | 0.66 | 1311 (<400, 6361) | 0.41 \(^a\) |
| Kenyan | 43 | 30 (70) | 1.06 (0.36, 3.09) | 0.80 | 1411 (<400, 28107) | |
| All | 78 | 56 (72) | 1.00 (0.34, 2.95) | 0.80 | 1368 (<400, 7477) | |

Differences in median viral load, baseline v. follow-up \(^b\): refugee, \( p = 0.04 \); Kenyan, \( p = 0.03 \); All, \( p = 0.002 \)

\(^a\)Mann-Whitney two-sample statistic (Wilcoxon rank-sum test)

\(^b\)Wilcoxon signed-rank test

Round Two

By the end of the Round Two follow-up period, 73% (116/159) of all Round One participants had been
engaged by a specialist adherence counselor and 3% (4/159) were switched to second-line ART. Among clients recruited in Round One, 60% (44/73) of refugees and 58% (50/86) of host nationals submitted a blood sample in Round Two. There were no differences between those with or without a follow-up viral load in relation to refugee status (p = 0.96), age (p = 0.46) and gender (p = 0.23). However, among the group participating in Round Two, higher proportions were married (50% vs 30%, p = 0.02) and had not travelled for ≥1 consecutive month in the past year (30% vs 14%, p = 0.03) (Additional file 5). Among refugees and host nationals who did not participate in Round Two, a greater proportion of the host national group had travelled for ≥1 consecutive month in the past year (Table 1). Among those who participated in both rounds, median viral load declined between rounds (5,010 copies/mL vs 1,368, p < 0.002). The follow-up result was similar for refugees and host nationals (1,311 copies/mL vs 1,411, p = 0.41). Among all who tested <5000 copies/mL in Round One, 63% (24/38) maintained viral suppression in Round Two (71%, 10/14 refugees; 58%, 14/24 host nationals). Proportions of refugees and host nationals suppressed in Round Two were similar (74% vs 70%, p = 0.66) (Table 2).

In samples submitted for drug resistance testing (n = 20; 8 refugees, 12 host nationals), 65% (13/20; 5 refugees, 8 host nationals) were successfully amplified. Of these, 69% (9/13) exhibited drug resistant mutations (4/5 refugees, 5/8 host nationals). Resistance to two drug classes was observed in 62% (8/13) of samples. The most prevalent mutations were M184V (NRTI-associated mutation) found in 54% (7/13) of samples and the K103N (NNRTI-associated mutation) found in 46% (6/13) of samples (Fig. 2). HIV-1 subtypes included sub-type A (62%; 8/13), C (15%; 2/13), and D (23%; 3/13).

**Discussion**

In this study, the first of its kind to compare adherence to ART and viral suppression among refugees and host nationals who accessed ART from a refugee camp clinic, we found unacceptably low proportions of viral suppression within both groups. Among those on treatment for ≥25 weeks in the Round One survey, only 50% had a viral load of <5000 copies/mL. There was weak evidence that refugees had attained a better viral response when compared with host nationals in the Round One survey (p = 0.10); however, in the final multivariable model refugee status was not associated with viral suppression. Proportions suppressed within each group were also similar in Round Two.

Although improved in Round Two, proportions virologically suppressed continued to be unacceptably low in relation to other resource-limited settings [18–20]. Although virologic data from conflict-affected populations are sparse, a South African study found that foreigners had improved chances of viral suppression when compared with locals [21]. In Kuala Lumpur, Malaysia, high proportions of refugees and host nationals were virologically suppressed (81% v. 84%, p = 0.54) [6]. Strong outcomes among refugees as measured by survival, CD4 counts and adherence were found in other conflict-affected settings [22–24]. In the present study, the overall proportion suppressed was lower in comparison to findings from a meta-analysis of 89 studies of sub-Saharan African HIV treatment programs that reported 67% viral suppression after 12 months of ART [25].

In the present study, with the exception of host national self-reports over the past month, mean adherence in Round One using any measurement was >85%. When assessing these findings in relation to viral response and leaving the possibility of drug resistance aside, it is
advisable that more sensitive measures of adherence be used for monitoring purposes, especially where laboratory monitoring is intermittent or unavailable. Notably, self-reported dosing, which was defined as an incorrect self-report of dosing schedule when compared with routine dosing schedules, was associated with lack of viral suppression. As ART tablets were distributed in small bags with non-standardized, handwritten dosing instructions, prescribed changes in the dosing or regimen may not have been understood. Improvements in Round Two outcomes suggested that basic program infrastructure, including supportive services, may have been lacking.

The effect of longer duration between HIV diagnosis and ART start on viral suppression (AOR: 3.98, 95% CI 1.44, 11.01; p-trend = 0.006) could have been related to effective patient monitoring that enabled better preparedness for ART when initiated in the home country or in the refugee camp setting. A shorter duration between diagnosis and initiation may signal a lack of engagement with health services. In other settings, delayed ART initiation was shown to be a barrier to retention in care [26, 27].

In drug resistance testing, 64% of successful amplifications exhibited resistance mutations. Assuming conservatively that the six unsuccessful amplifications tested negative, 45% of samples would still have exhibited major resistance mutations. This suggests that drug resistance may be a serious problem within this population. In 2011, eight years after ART roll-out in East Africa, the estimated prevalence of drug resistance among ART-naive individuals was 7.4% and was increasing by 29% per year [28]. In two contrasting Kenyan studies, the prevalence of transmitted resistance between 2008 and 2010 was 1.1% in a rural setting and 13.2% in an urban setting [29, 30]. Higher levels of drug resistance in our study population could have been linked to a history of treatment interruptions before, during, or after displacement, but prior to the self-reported recall period used to assess adherence in our survey. This could help to explain the discordance we detected between adherence and viral suppression, whereby proportions suppressed were much lower than what adherence levels would suggest. Early-warning indicators for drug resistance in African settings depend on prescribing practices, patient retention, continuity of drug supply, and viral suppression; therefore, effective patient monitoring is critical when drug resistance testing is not routinely available [31, 32].

Some important factors were not assessed in this study. These included the effects of very high viral loads at ART start, reduced potency of medications resulting from hot storage conditions, and acute malnutrition. Very high viral loads (≥100,000 copies/mL) are associated with a lower likelihood of ever achieving viral suppression [33]. Since viral load testing had not previously been implemented among this population, it was not possible to evaluate this possibility. In Round One, however, 15% (24/159) had a viral load in excess of 100,000 copies/mL. Although we did not measure acute malnutrition quantitatively, in accompanying qualitative work many clients reported that they were food insecure and believed that ART was toxic when taken without sufficient food [34]. Associations between food insecurity, viral load and mortality have been reported in other populations [35, 36] and are thought to be mediated by drug absorption and adherence [37–40]. Future studies conducted in refugee settings should use a sensitive measure of food insecurity to assess its true impact. Finally, we did not test the potency of medications, therefore any impact of storage conditions on potency could not be determined. The average annual temperature in Kakuma is 28 °C and can reach 40 °C or more in the dry season. The medications were stored in an indoor room that was not air conditioned.

This study had several limitations. Adherence self-reports may have suffered from recall and/or social desirability biases. As the host national community were primarily Turkana, a highly mobile group, findings may not be generalizable to other Kenyan host nationals. Bias may have been introduced to our comparisons of refugees and host nationals if a local clinic at Kakuma Mission Hospital had served healthier HIV-positive Kenyans. We could not assess this bias as we did not study this clinic. Risk factors were not assessed in Round Two due to a lack of resources to implement a follow-up survey questionnaire. Differences in mobility between refugees and host nationals may have introduced bias if one group had been less likely to participate in Round Two [41, 42]. If this had resulted in a lower likelihood of refilling prescriptions, for example, viral suppression could have been overestimated in one group compared with the other. The fact that few clients in Round Two had travelled for at least one consecutive month in the year prior to the study when compared with those who participated only in Round One, suggested that the Round Two cohort was more stable. Interestingly, the Round Two cohort included a greater proportion of host nationals who had travelled outside of the camp for one month or more in the year prior to the study, yet fewer were virologically suppressed in comparison to the refugee group. Although the overall n was small, a notable strength of the study was its relative completeness as 85% of all eligible clients were initially recruited. Strong efforts were made to mitigate recall and social desirability biases by conducting face-to-face interviews with well-trained local researchers. As Kakuma was founded in 1992, this setting was relatively stable and, arguably...
Conclusions

In summary, unacceptably low proportions of refugees and host nationals were virologically suppressed in cross-sectional surveys conducted at two time-points. A remedial intervention that strengthened clinic procedures and adherence support between the surveys may have helped to improve outcomes; however, this finding was tentative given attrition between survey rounds. The proportions suppressed at <5000 copies/mL in Round Two were still unacceptably low, and drug resistance mutations were found in a high proportion of those who were not suppressed. Overall, there were only minor differences between refugees and host nationals across outcome measures, suggesting that socio-structural factors operating at the clinic level, not refugee status, were the best explanation for observed levels of viral suppression. Future work should evaluate interventions to improve adherence counseling, monitoring, and viral suppression across the range of settings where refugees and host nationals share HIV services, including acute and longer-term humanitarian settings and settings located outside of formal encampments. Within the framework of a public health approach to ART focused on increasing levels of viral suppression by retaining patients across the HIV cascade of care, these results have highlighted the importance of laboratory and counseling services for vulnerable populations who access services in remote settings. Given that early detection of treatment failures can prevent drug resistance [43] and consistent viral suppression limits onward HIV transmission [44], routine viral load testing using dried blood spots and/or point of care devices should be adopted in view of the potential long-term benefits. This study serves as a clear reminder that programs operating in remote settings should monitor performance carefully in an effort to maintain consistently high levels of viral suppression.

Additional files

**Additional file 1:** Association of contextual factors with suppressed viral load among refugees and host community on ART for ≥25 weeks at baseline in Kakuma, Kenya (N=128*). (DOC 42 kb)

**Additional file 2:** Association of self-change factors with suppressed viral load among refugees and host community on ART for ≥25 weeks at baseline in Kakuma, Kenya (N=128*). (DOC 42 kb)

**Additional file 3:** Association of adherence measures (action state factors) with viral suppression among refugees and host nationals on ART for ≥25 weeks at baseline (Round One) in Kakuma, Kenya (N=128*). (DOC 38 kb)

**Additional file 4:** Mean adherence among refugees and host nationals at baseline (Round One) in Kakuma, Kenya. (DOX 15 kb)

**Additional file 5:** Socio-demographic comparison of ART clients with and without a follow-up (Round Two) viral load in Kakuma, Kenya. (DOC 37 kb)

**Abbreviations**

ART: antiretroviral therapy; IQR: interquartile range; IRC: International Rescue Committee; UNHCR: United Nations High Commissioner for Refugees; NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; WHO: World Health Organization; KEMRI: Kenya Medical Research Institute; CI: confidence interval; OR: odds ratio; AOR: adjusted odds ratio; PI: protease inhibitor

**Acknowledgements**

The authors wish to thank the study participants, the research team, the local and refugee home-based care teams, the HIV Comprehensive Care Clinic staff, and the International Rescue Committee for their tremendous support. We acknowledge Neal Alexander who provided statistical advice and Nadine Cornier who provided assistance with study implementation. Thanks to Clayton Anyongo and Frank Angira for comments on a previous draft. The authors acknowledge the National Council for Science and Technology of Kenya and the Kenya Medical Research Institute for granting permissions to conduct this work.

**Funding**

JBM acknowledges financial support provided by Canadian Institutes of Health Research (Doctoral Research Award Priority Announcement for HIV/AIDS #200710IDB), the Parkes Foundation (PhD Grant Fund), the London School of Hygiene and Tropical Medicine (Research Training Support Grant), and the United Nations High Commissioner for Refugees (UNHCR). UNHCR, but not the other funders, assisted in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication.

**Authors’ contributions**

JBM designed the research protocol, managed data collection, completed statistical analyses, and wrote the first draft of the manuscript. PS, SD, MS, NP, JW, IM, IN, ES, AG, and DAR helped design the study; collection, management, analysis, and interpretation of the data; preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication.

**Ethics approval and consent to participate**

Ethical approval was obtained from the Kenya Medical Research Institute (Approval 1884) and the London School of Hygiene and Tropical Medicine Research Ethics Committee (Approval 5547). Participation in the study was voluntary and informed consent was obtained from all participants. Consent forms were translated into Swahili, Juba Arabic, Somali Bantu, Amharic, and Turkana. Translators were employed for participants who spoke other dialects. Forms were translated into Swahili, Juba Arabic, Somali Bantu, Amharic, and Turkana. Translators were employed for participants who spoke other dialects. A record of consent was obtained by signature or thumbprint.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Author details

1 College of Health Professions, Pace University, New York, NY, USA. 2MRC Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom. 3Public Health and HIV Unit, United Nations High Commission for Refugees, Geneva, Switzerland. 4Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom. 5East Africa Regional Office, United Nations High Commission for Refugees, Nairobi, Kenya. 6Center for Global Health Research and HIV-Research Laboratory, Kenya Medical Research Institute, Kisumu, Kenya. 7National AIDS/STD Control Program, Nairobi, Kenya. 8Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, United Kingdom. 9World Health Organization, Geneva, Switzerland. 10Center for Refugee and Disaster Response, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA. 11Clinical and Laboratory Standards Institute, Centers for Disease Control and Prevention Program-Kenya, Kisumu, Kenya.

Received: 26 May 2016 Accepted: 6 March 2017

References

1. Centre for Research on Epidemiology of Disasters. People affected by conflict 2013: Humanitarian needs in numbers. Brussels: Centre for Research on Epidemiology of Disasters; 2013.
2. UNHCR. Statistical Yearbook 2013, 13th edition. Geneva: UNHCR; 2014.
3. United Nations General Assembly. Convention Relating to the Status of Refugees, 28 July 1951, United Nations, Treaty Series, vol. 189, p. 137. Entry into force 22 April 1954, in accordance with article 43.
4. Mendelsohn JB, Schilperoord M, Spiegel P, Ross DA. Adherence to antiretroviral therapy and treatment outcomes in conflict-affected and forcibly displaced populations: a systematic review. Confl Health. 2012;6(9):epub.
5. Griffiths K, Ford N. Provision of antiretroviral care to displaced populations in humanitarian settings: a systematic review. Med Confl Surviv. 2013;29(3):198–215.
6. Mendelsohn JB, Schilperoord M, Spiegel P, Balasundaram S, Radhakrishnan A, Lee CK, et al. Is forced migration a barrier to treatment success? Similar HIV treatment outcomes among refugees and a surrounding host community in Kuala Lumpur, Malaysia. AIDS Behav. 2014;18(2):323–34.
7. Spiegel PB, Checchi F, Colombo S, Paik E. Health-care needs of people affected by conflict: future trends and changing frameworks. Lancet. 2010;375(9711):341–5.
8. UNHCR, Southern African HIV Clinicians Society. Clinical guidelines for antiretroviral therapy management for displaced populations. Geneva: UNHCR; 2007.
9. Centers for Disease Control and Prevention. Changing lives in Kenya's Kakuma Refugee Camp 2013. Available from: http://www.cdc.gov/globalaids/success-stories/kenyarefugeecamp.html.
10. Finitis DJ, Pellowis JA, Huerdo-Medina TB, Fox MC, Kalichman SC. Visual analogue scale (VAS) measurement of antiretroviral adherence in people living with HIV (PLWH) - a meta-analysis. J Behav Med. 2016;39(6):1045–55.
11. Sangera RZ, Mosha F, Prosperi M, Abood S, Vercauteren J, Kamacho RJ, et al. Pharmacy refill adherence outperforms self-reported methods in predicting HIV therapy outcome in resource-limited settings. BMC Public Health. 2014;14:1035.
12. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013.
13. Woods CK, Brumme CJ, Liu TF, Chui CK, Chu AL, Wynhoven B, et al. Automating HIV drug resistance genotyping with RECal, a freely accessible sequence analysis tool. J Clin Microbiol. 2012;50(6):1936–42.
14. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42(11):1608–18.
15. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer RW, et al. Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med. 2013;21(1):16–14.
16. Ewart C. Social-action theory for a public health psychology. Am Psychol. 1991;46(9):931–46.
17. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology. 2009;20(4):488–95.
18. Ahoua L, Guenther G, Pinoges L, Anguzu P, Chaix ML, Le Tiec C, et al. Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural southwestern Uganda. BMC Infect Dis. 2009;9:85.
19. Amendo M, Alonso E, Eisenberg N, Ibanez L, Ferreyra C, Jaen A, et al. Monitoring HIV viral load in resource limited settings: still a matter of debate? PloS one. 2012;7(12):e47391.
20. McMahon JH, Elliott JH, Bertagnolli S, Kubiak R, Jordan MR. Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review. Bull World Health Organ. 2013;91(5):377–86E.
21. McCarthy K, Chenchis MF, Veeney J, Meyer-Rath G, Jaffer A, Simpfowohl S, et al. Good treatment outcomes among foreigners receiving antiretroviral therapy in Johannesburg, South Africa. Int J STD AIDS. 2009;20:658–62.
22. Kiboneka A, Nyatya RJ, Njabiro C, Anema A, Cooper CL, Fernandes KA, et al. Combination antiretroviral therapy in population affected by conflict: outcomes from large cohort in northern Uganda. BMJ. 2009;338:b201.
23. O'Brien DP, Venis S, Greig J, Shanks L, Ellman T, Sabaphaty K, et al. Provision of antiretroviral treatment in conflict settings: the experience of Médecins Sans Frontières. Confl Health. 2010;4:12.
24. Cubert H, Tu D, O'Brien DP, Ilmman T, Mills C, Ford N, et al. HIV treatment in a conflict setting: outcomes and experiences from Bukavu, Democratic Republic of the Congo. PloS Med. 2007;4(5):e129.
25. Barth Schreus R, van der Loeff MR, Soeters R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2010;10(3):155–66.
26. Amoru B, Namara G, Birungi J, Nabiyo C, Levin J, Grosskurth H, et al. Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health. 2009;9:290.
27. Loeina E, Bassett IV, Giddy J, Chetty S, Regan S, Walensky RP, et al. The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PloS one. 2010;5(3):e9538.
28. Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DH, Gregson J, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet. 2012;380(9849):1250–63.
29. Hassan AS, Mwaringa SM, Obonyo CA, Nabwera HM, Sanders EJ, Rinke de Wit TF, et al. Low prevalence of transmitted HIV type 1 drug resistance among antiretroviral-naive adults in a rural HIV clinic in Kenya. AIDS Res Hum Retrovir. 2013;29(11):129–35.
30. Sigalloff KC, Mandalaya K, Hamers RL, Oteino F, Jao IM, Lyagoba F, et al. Short communication: high prevalence of transmitted antiretroviral drug resistance among newly HIV type 1 diagnosed adults in Mombasa, Kenya. AIDS Res Hum Retrovir. 2012;28(9):1033–7.
31. Sigalloff KC, Hamers RL, Menke J, Labib M, Siwale M, Ipe V, et al. Early warning indicators for population-based monitoring of HIV drug resistance in 6 African countries. Clin Infect Dis. 2012;54 Suppl 4:S294–9.
32. Mugyenyi P, Walker AS, Hakim J, Munderi P, Gibb DM, Kittyo C, et al. Routine venus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DAFT): a randomised non-inferiority trial. Lancet. 2010;375(9709):123–31.
33. Wood E, Hogg RS, Yip B, Harrigan PR, Montaner J. Why are baseline HIV RNA levels 100,000 copies/mL or greater associated with mortality after the initiation of antiretroviral therapy? J Acquir Immune Defic Syndr. 1999;25(3):289–95.
34. Mendelsohn JB, Rhodes T, Spiegel P, Schilperoord M, Burton JW, Balasundaram S, et al. Bounded agency in humanitarian settings: a qualitative study of adherence to antiretroviral therapy among refugees situated in Kenya and Malaysia. Soc Sci Med. 2014;120:387–95.
35. Weiser SD, Frongillo EA, Ragland K, Hogg RS, Riley ED, Bangsberg DR. Food insecurity is associated with incomplete HIV RNA suppression among newly HIV type 1 diagnosed adults in Mombasa, Kenya. PLoS Med. 2010;7(12):e1001033.
36. Weiser SD, Frongillo EA, Ragland K, Hogg RS, Riley ED, Bangsberg DR. Food insecurity is associated with incomplete HIV RNA suppression among newly HIV type 1 diagnosed adults in Mombasa, Kenya. AIDS Res Hum Retrovir. 2012;28(9):1033–7.
37. Drain PK, Kupca R, Mugusi F, Fawzi WW. Micronutrients in HIV-positive persons receiving highly active antiretroviral therapy. Am J Clin Nutr. 2007;85(2):333–45.
38. Hardon AP, Akurut D, Comoro C, Ekezie C, Irunde HF, Gerrits T, et al. Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care. 2007;19(5):658–65.
39. Weiser SD, Tuiller DM, Frongillo EA, Senkungu J, Mukibi N, Bangsberg DR. Food insecurity as a barrier to sustained antiretroviral therapy adherence in Uganda. PLoS one. 2010;5(4):e10340.
40. Nagata JM, Magererenge RO, Young SL, Oguta JO, Weiser SD, Cohen CR. Social determinants, lived experiences, and consequences of household food insecurity among persons living with HIV/AIDS on the shore of Lake Victoria, Kenya. AIDS Care. 2011;24(6):728–36.
41. UNHCR. Changing regional trends in HIV-related behaviours in refugee camps and surrounding communities. Geneva: UNHCR; 2011.
42. UNHCR. Behavioural surveillance surveys among refugees and surrounding host population (Kakuma, Kenya). Geneva: UNHCR; 2004.
43. Hamers RL, Sigaloff KC, Wensing AM, Wallis CL, Kityo C, Siwale M, et al. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis. 2012;54(11):1660–9.
44. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
45. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents 2012 [cited 2012 30 July]. Available from: http://www.aidsinfo.nih.gov/contentfiles/ivguide/adultandadolescentgl.pdf.